Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Ritonavir Interaction Study
NCT02171754Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2009
- Primary completion
- Dec 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of afatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve from 0 to infinity up to 6 days, Area under the concentration-time curve from 0 to last quantifiable data point up to 6 days and 1 more. Started Sep 2009; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02171754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02171754.